Ad is loading...
GEBIX
Price
$10.09
Change
-$0.02 (-0.20%)
Updated
Nov 15 closing price
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

GEBIX vs RNWFX

Header iconGEBIX vs RNWFX Comparison
Open Charts GEBIX vs RNWFXBanner chart's image
Goldman Sachs ESG Em Mkts Eq Inst
Price$10.09
Change-$0.02 (-0.20%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
GEBIX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GEBIX vs. RNWFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GEBIX is a StrongBuy and RNWFX is a Hold.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. GEBIX (22.2M). GEBIX (1.57) and RNWFX (1.51) have matching dividends . GEBIX was incepted earlier than RNWFX: GEBIX (6 years) vs RNWFX (23 years). GEBIX is a more actively managed with annual turnover of: 54.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than GEBIX: RNWFX (250) vs GEBIX (1000000). GEBIX annual gain was more profitable for investors over the last year : 13.99 vs. RNWFX (11.54). RNWFX return over 5 years is better than : 17.17 vs. GEBIX (3.70).
GEBIXRNWFXGEBIX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years23 years-
Gain YTD11.2467.099158%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets22.2M60.9B0%
Annual Yield % from dividends1.571.51104%
Returns for 1 year13.9911.54121%
Returns for 3 years-28.24-14.55194%
Returns for 5 years3.7017.1722%
Returns for 10 yearsN/A41.00-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics